Late HCC onset after DAAs therapy in patients with SVR: a type D ADR that requires a longer follow-up?

MLA

Nunzia Papa, et al. “Late HCC Onset after DAAs Therapy in Patients with SVR: A Type D ADR That Requires a Longer Follow-Up?” European Journal of Hospital Pharmacy, vol. 26, June 2019, pp. 243–44. EBSCOhost, https://doi.org/10.1136/ejhpharm-2019-001975.

APA

Nunzia Papa, Alessandro Perrella, Micaela Spatarella, Adelaide Maddaloni, Luigi Elio Adinolfi, Pasquale Bellopede, Luca Rinaldi, Antonio Izzi, Antonella Nappi, Costanza Sbeglia, & Rodolfo Punzi. (2019). Late HCC onset after DAAs therapy in patients with SVR: a type D ADR that requires a longer follow-up? European Journal of Hospital Pharmacy, 26, 243–244. https://doi.org/10.1136/ejhpharm-2019-001975

Chicago

Nunzia Papa, Alessandro Perrella, Micaela Spatarella, Adelaide Maddaloni, Luigi Elio Adinolfi, Pasquale Bellopede, Luca Rinaldi, et al. 2019. “Late HCC Onset after DAAs Therapy in Patients with SVR: A Type D ADR That Requires a Longer Follow-Up?” European Journal of Hospital Pharmacy 26 (June): 243–44. doi:10.1136/ejhpharm-2019-001975.